Holen Sie sich die Stockscreener-App
3.58
1.42%
0.05
Schlusskurs vom Vortag:
$3.53
Offen:
$3.675
24-Stunden-Volumen:
13,239
Relative Volume:
0.06
Marktkapitalisierung:
$1.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.03M
KGV:
-0.0289
EPS:
-124.0371
Netto-Cashflow:
$-6.53M
1W Leistung:
-8.91%
1M Leistung:
-37.74%
6M Leistung:
-59.62%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.47
$3.78
1-Wochen-Bereich:
$3.47
$4.08
52-Wochen-Spanne:
$3.47
$16.92
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Firmenname
Decoy Therapeutics Inc
Sektor
Branche
Telefon
346-772-0346
Adresse
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
3.58 | 1.92M | 0 | -13.03M | -6.53M | -124.04 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-23 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc Aktie (DCOY) Neueste Nachrichten
Armistice Capital (DCOY) discloses 65,503-share, 9.99% holding in Decoy Therapeutics - Stock Titan
DCOY Q2'26 Earnings: EPS estimate is (2.88) USD - TradingView
Decoy Therapeutics: Q2 Earnings Snapshot - Yahoo Finance
Decoy Therapeutics Inc. Q2 2026: Revenue $0.23M, Net loss $(2.37M), EPS $(4.46) — 10-Q Summary - TradingView
Decoy Therapeutics (DCOY) posts wider Q2 loss, flags going-concern and Nasdaq risks - Stock Titan
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform - Morningstar
Decoy Therapeutics expands IP portfolio to 19 applications - Investing.com
Decoy's antiviral applications span 7 jurisdictions, with 19 pending - Stock Titan
Decoy Therapeutics (DCOY) director files Form 3 showing zero insider holdings - Stock Titan
Decoy Therapeutics (DCOY) Advances Research on D-MAV Candidates for Filoviruses - GuruFocus
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAVtm Platform into High Consequence Global Health Threats - Lelezard
Decoy Therapeutics’ D-MAV platform shows inhibition of Ebola Zaire virus - TipRanks
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats - Morningstar
Decoy candidate shows activity against Ebola and Lassa in tests - Stock Titan
Decoy Therapeutics Inc. Revenue Breakdown – MUN:FP11 - TradingView
Decoy Therapeutics (DCOY) pursues warrant approvals and cuts authorized shares - Stock Titan
Decoy Therapeutics Inc. (NASDAQ: DCOY) Share Price, DCOY Stock News, DCOY Share Price & Updates - Kalkine
Decoy Therapeutics Inc. Revenue Breakdown – FWB:FP11 - TradingView
Decoy Therapeutics Inc. SEC Filing (Jul 20, 2026) - Stock Titan
$5.86 | Decoy Therapeutics Inc. Common Stock (DCOY) Stock Price Today - Binance
DCOY Q3 2024 Earnings: Smaller-than-Expected Loss Signals Cost Discipline Amid Clinical ProgressSaaS Earnings Trends - dars.gov.et
Enterprise value to EBITDA forward of Decoy Therapeutics Inc. – FWB:FP11 - TradingView
Enterprise value to EBIT forward of Decoy Therapeutics Inc. – FWB:FP11 - TradingView
Decoy Therapeutics Inc. (DCOY) Files 8-K: Key Company Information, Address, and Nasdaq Listing Details (July 2026) - Minichart
Decoy Therapeutics (DCOY) Jumps 7.5%: Support Holds While Resistance LoomsStrong Buy Stocks - dars.gov.et
Decoy Therapeutics (Nasdaq: DCOY) details 2026 annual meeting votes - Stock Titan
Decoy Therapeutics Inc. Elects Patricia Gauthier as Class II Director - marketscreener.com
Decoy Therapeutics elects Patricia Gauthier to board By Investing.com - Investing.com Nigeria
Decoy Therapeutics elects Patricia Gauthier to board - Investing.com
Decoy Therapeutics Appoints New Board Member - Intellectia AI
Press Release: Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors - Moomoo
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors - Nasdaq
Decoy Therapeutics Company Profile & Introduction - Moomoo
Price to earnings forward of Decoy Therapeutics Inc. – NASDAQ:DCOY - TradingView
Price to book forward of Decoy Therapeutics Inc. – MUN:FP11 - TradingView
Price to sales forward of Decoy Therapeutics Inc. – MUN:FP11 - TradingView
Enterprise value to revenue forward of Decoy Therapeutics Inc. – MUN:FP11 - TradingView
Decoy Therapeutics (DCOY) Stock Forum and Discussion - Moomoo
Form S-1 Decoy Therapeutics Inc For: 10 July - Investing.com India
DCOY Announces Share Offering by Stockholders - GuruFocus
Decoy Therapeutics files prospectus for 3.767M share offering - scanx.trade
Decoy Therapeutics Files to Register Up to 3.77 Million Shares for Resale - Moomoo
Form S-1 Decoy Therapeutics Inc For: 10 July By Investing.com - Investing.com South Africa
Decoy Therapeutics (DCOY) Slides 5% as Stock Tests Key Support at $5.65Total Put Call - dars.gov.et
Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London - AOL.com
DCOY Q3 2024 Earnings: Significant EPS Surprise Despite Stock DeclineRevenue Surprise History - dars.gov.et
Decoy stock rises after announcing up to $21 million private placement financing - MSN
DCOYDecoy Therapeutics Inc Latest SEC Filings - Finviz
DCOY Q3 2024 Earnings: Narrower-than-Expected Loss Fails to Stem Stock DeclineEarnings Quality Analysis - dars.gov.et
Decoy Therapeutics (DCOY) Slides 4.7% as Selling Pressure IntensifiesMAMA Signal - dars.gov.et
Finanzdaten der Decoy Therapeutics Inc-Aktie (DCOY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):